{
    "clinical_study": {
        "@rank": "65290", 
        "arm_group": [
            {
                "arm_group_label": "2677TT", 
                "arm_group_type": "Experimental", 
                "description": "Plasma kinetics of fluvoxamine and digoxin in this genotype"
            }, 
            {
                "arm_group_label": "2677GG", 
                "arm_group_type": "Other", 
                "description": "plasma kinetics of fluvoxamine and digoxin in this genotype"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will compare plasma kinetics of two marker drugs in individuals with\n      different genetic variations in the MDR1-gene. The hypothesis is that one group will have\n      higher exposure than the other."
        }, 
        "brief_title": "Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  - Healthy volunteer \u2265 18 years of age\n\n          -  Normal kidney function as measured by GFR according to Cockroft-Gault (70-120 ml/min)\n\n          -  Normal P-potassiumvalue (3,6-4,6 mmol/L)\n\n          -  HF>50 and no AV-block on resting ECG. No other significant abnormalities as judged by\n             the investigator.\n\n          -  Subject giving written informed consent\n\n          -  Subject capable of understanding instructions\n\n        Exclusion Criteria:\n\n          -  - Pregnancy\n\n          -  Ongoing infection\n\n          -  Intake of  medication, including natural remedies (for example St John\u00b4s wort),\n             within one month prior to starting study except for paracetamol.\n\n          -  Active drug or alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704638", 
            "org_study_id": "fluvoxaminedigoxin"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "2677TT", 
                    "2677GG"
                ], 
                "intervention_name": "fluvoxamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "2677TT", 
                    "2677GG"
                ], 
                "intervention_name": "Digoxin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Digoxin", 
                "Fluvoxamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 10, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden"
                }, 
                "name": "CPTU"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "last_name": "Georgios Panagiotidis, MD PhD DDS", 
            "phone": "+46858582678"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: has been evaluated as not needing oversight from Medical Products Agency by them.", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The participants are administered a single dose of fluvoxamine or digoxin. Plasma kinetics of fluvoxamine are followed for 36 hours. Plasma kinetics of digoxin are followed for 48 hours. There is a washout period between the both parts.", 
            "measure": "Cmax of fluvoxamine and of digoxin", 
            "safety_issue": "No", 
            "time_frame": "2 days for fluvoxamine and 2 days for digoxin. Washout period of at least 1 week between the both parts. Total study time maximum 4 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704638"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska Institutet", 
            "investigator_full_name": "Erik Sparve", 
            "investigator_title": "MD, specialist in clinical pharmacology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Karolinska Institutet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karolinska Institutet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2008", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}